Canada Research Chair in Development of Personalized Therapies for Ovarian Cancer Patients

Ovarian cancer is the fifth leading cause of cancer-related death in women and the deadliest gynecological disease. Although new treatments have recently been approved, drug resistance remains a major challenge. There is an urgent need for new personalized approaches to prevent the development of drug resistance in patients with ovarian tumours.

Professor Marilyne Labrie, Canada Research Chair in Development of Personalized Therapies for Ovarian Cancer Patients, has already demonstrated that cancer cells’ adaptive responses to stress represent an opportunity to provide personalized therapeutics that could delay or prevent drug resistance. Now, she and her research team are studying how ovarian tumours adapt to various types of endogenous (internal), environmental and therapeutic stressors.

This research program will help define stress-related therapeutic vulnerabilities and lead to personalized therapeutic approaches.

• Canada Research Chairs Program
• Canadian Institutes of Health Research

Additional Information

• Tier 2 Chair - 2022-04-01